1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc.

TTSE:4893
89.00
JPY
-2.00
(-2.20%)
5.25BMarket Cap
Nov 13Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.37
2.45
15.98
7.64
0.18
0.12
- -
Basic EPS, GAAP
-15.48
-19.33
-9.87
-27.25
-22.28
-18.33
- -
Free Cash Flow per Basic Share
-7.31
-18.9
-2.74
-21.05
-20.5
-17.37
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
63.19
101.78
104.59
131.42
109.13
90.8
82.36
Tangible Book Value per Share
63.19
101.78
104.59
131.42
109.13
90.8
82.36
Basic Weighted Avg Shares
41
41
39
41
43
43
43
Sales/Revenue/Turnover
97
101
626
317
8
5
- -
Operating Margin (%)
-621.4
-761.93
-16.99
-244.74
-14,092.29
-15,945.08
- -
Depreciation Expense
13
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-637
-795
-387
-1,130
-964
-794
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-654.47
-789.26
-61.78
-356.68
-12,711.94
-15,870.72
- -
Working Capital
2,588
4,145
4,249
5,631
4,706
3,909
3,552
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
2,598
4,185
4,301
5,687
4,725
3,932
3,575
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-23.44
-9.11
-22.63
-18.52
-18.33
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
43
43
43
Market Capitalization
8,660
6,235
5,251

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
5,062
- -
3,637
Cash, Cash Equivalents & STI
4,947
- -
3,545
Accounts Receivable, Net
- -
- -
- -
Inventories
12
- -
2
Total Current Liabilities
76
- -
85
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.47%
-16.79%
Free Cash Flow
- -
154.66%
-15.27%
Net Income, GAAP
- -
26.68%
-17.72%
Sales/Revenue/Turnover
- -
68.74%
-34.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
- -
- -
- -
8
2025
- -
- -
- -
- -
5
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-7.86
-7.93
- -
- -
-22.28
2025
- -
- -
- -
- -
-18.33
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Koji Tamada
Full Time Employees
23
Sector
Health technology
Industry
Pharmaceuticals: major
Address
T&G Hamamatsucho Building Tokyo Japan 105-0012
IPO Date
Jun 28, 2023
Website
noile-immune.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Noile-Immune Biotech Inc. develops chimeric antigen receptor T-cell (CAR-T) therapies targeting solid tumors using its proprietary PRIME technology, exclusively licensed from Yamaguchi University; the company's pipeline includes in-house candidates such as NIB101, NIB102, NIB103, and NIB104, alongside co-development programs like ADAP01 with Adaptimmune Therapeutics plc and AUTL01 with Autolus Therapeutics plc; PRIME enhances CAR-T cell efficacy by expressing IL-7 and CCL19 to activate both engineered T cells and the host immune system, positioning it as a platform applicable to TCR-T cells and other immunotherapies. Founded in 2015 and headquartered in Minato-ku, Tokyo, Japan, with additional facilities in Yamaguchi and Fujisawa, Kanagawa, the company operates primarily in Japan while pursuing global partnerships in the oncology segment focused on cancer immunotherapy drug discovery. Recent developments include the termination of its license agreement with Takeda Pharmaceutical for NIB102 and NIB103 in June 2024, followed by pipeline re-prioritization; completion of clinical trial notification submission for NIB103 Phase I in June 2025; adoption of subsidies from Yamaguchi Prefecture and Ube City in July 2025 for advancing solid tumor CAR-T treatments; and patent registration in Japan in November 2025 for technology related to its developments.